Literature DB >> 2149516

Regression of left ventricular hypertrophy and systolic function in hypertensive patients during long-term treatment with ketanserin.

V Coto1, M Cocozza, U Oliviero, A Lucariello, T Picano, B Castaldo, V Iovino, L Cacciatore.   

Abstract

It is now generally accepted that antihypertensive therapy can induce regression of left ventricular hypertrophy (LVH) in hypertensive subjects. However, the influence of LVH reversal on both the systolic and diastolic functions, and particularly the ability of the heart to meet sudden overloads caused by exercise and/or recurrence of hypertension, remain unanswered questions. The long-term effects of ketanserin, a selective serotonin S2-receptor antagonist with additional alpha 1-adrenergic blocking properties, on LVH and systolic function were studied in 13 untreated subjects (age range 35-55 years) with mild-to-moderate essential hypertension, echocardiographic evidence of LVH, and normal ejection fraction. Blood pressure values and echocardiographic measurements of dimensions, wall thicknesses, and indices of LV mass were determined before and after 3, 6, and 12 months treatment; ejection fractions at rest and during exercise were evaluated by equilibrium multigated radionuclide angiocardiography at baseline and after 12 months of therapy. Mean arterial pressure was significantly reduced from the first month of treatment (p less than 0.001) and remained well controlled up to the end of the trial. Both posterior and septum wall thicknesses decreased after 3 months of therapy and remained stable throughout the whole study period. LV mass index decreased from a mean +/- SD of 187.7 +/- 47.6 g/m2 to a mean of 157.81 +/- 31.63 g/m2 (p less than 0.01) at the third month, reaching greater decreases after 6 months (156.05 +/- 31.00 g/m2) and after 12 months (153.21 +/- 28.80 g/m2) of treatment. A significant correlation was found between LV mass and posterior wall thickness at the different observation times in the study. Finally, the regression of LVH at the end of therapy was not associated with impairment of systolic function, as assessed by measurements of ejection fraction at rest and during exercise.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149516     DOI: 10.1007/bf00053432

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  14 in total

1.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

Authors:  R B Devereux; D R Alonso; E M Lutas; G J Gottlieb; E Campo; I Sachs; N Reichek
Journal:  Am J Cardiol       Date:  1986-02-15       Impact factor: 2.778

2.  Cardiac hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; P A Khairallah; F M Bumpus
Journal:  Circ Res       Date:  1974-11       Impact factor: 17.367

3.  Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study.

Authors:  W B Kannel; T Gordon; D Offutt
Journal:  Ann Intern Med       Date:  1969-07       Impact factor: 25.391

4.  Role of blood pressure in the development of congestive heart failure. The Framingham study.

Authors:  W B Kannel; W P Castelli; P M McNamara; P A McKee; M Feinleib
Journal:  N Engl J Med       Date:  1972-10-19       Impact factor: 91.245

5.  Changes in ventricular septal thickness during diuretic therapy.

Authors:  J I Drayer; J M Gardin; M A Weber; W S Aronow
Journal:  Clin Pharmacol Ther       Date:  1982-09       Impact factor: 6.875

Review 6.  Beta blockers and left ventricular hypertrophy in hypertension.

Authors:  B Trimarco; N De Luca; A Cuocolo; B Ricciardelli; G Rosiello; G Lembo; M Volpe
Journal:  Am Heart J       Date:  1987-10       Impact factor: 4.749

7.  Radionuclide measurements of diastolic function for assessing early left ventricular abnormalities in the hypertensive patient.

Authors:  M Caruana; I Al-Khawaja; A Lahiri; J Lewis; E B Raftery
Journal:  Br Heart J       Date:  1988-02

Review 8.  Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.

Authors:  P Vanhoutte; A Amery; W Birkenhäger; A Breckenridge; F Bühler; A Distler; J Dormandy; A Doyle; E Frohlich; L Hansson
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

Review 9.  Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy?

Authors:  E D Frohlich; R C Tarazi
Journal:  Am J Cardiol       Date:  1979-10-22       Impact factor: 2.778

10.  The influence of sympathetic nervous activity on regression of cardiac hypertrophy.

Authors:  B E Strauer; F Bayer; H M Brecht; W Motz
Journal:  J Hypertens Suppl       Date:  1985-12
View more
  2 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients.

Authors:  G P Vyssoulis; E A Karpanou; C E Pitsavos; T K Kourtis; A A Paleologos; P K Toutouzas
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.